Selective expression of folate receptor β and its possible role in methotrexate transport in synovial macrophages from patients with rheumatoid arthritis

Arthritis and Rheumatism

Volumn 42, Issue 8, 1999, Pages 1609-1616

  Nakashima Matsushita, Noriko ^a   Homma, Toshio ^a   Yu, Su ^a   Matsuda, Takemasa ^b   Sunahara, Nobuhiko ^b   Nakamura, Tadashi ^c   Tsukano, Michishi ^c   Ratnam, Manohar ^d   Matsuyama, Takami ^a  

^a KAGOSHIMA UNIVERSITY   (Japan)

^b Kagoshima Red Cross Hospital   (Japan)

^c Kumamoto Naika Hospital   (Japan)

^d MEDICAL COLLEGE OF OHIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD14 ANTIGEN; CELL RECEPTOR; FOLIC ACID; FOLIC ACID ANTAGONIST; MESSENGER RNA; METHOTREXATE; REDUCED FOLATE CARRIER;

ARTICLE; CELL SUBPOPULATION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG TRANSPORT; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; MACROPHAGE; NORTHERN BLOTTING; PRIORITY JOURNAL; RECEPTOR BINDING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHEUMATOID ARTHRITIS; SYNOVIUM; WESTERN BLOTTING;

ANTIGENS, CD14; ARTHRITIS, RHEUMATOID; BIOLOGICAL TRANSPORT; CARRIER PROTEINS; FOLIC ACID; HUMANS; METHOTREXATE; MONOCYTES; RECEPTORS, CELL SURFACE; RNA; SYNOVIAL MEMBRANE;

EID: 0033509413     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(199908)42:8<1609::AID-ANR7>3.0.CO;2-L     Document Type: Article

References (45)

1. Furst DE, Kremer JM. Methotrexate in rheumatoid arthritis. Arthritis Rheum 1988;31:305-14.
2. Kremer JM. Methotrexate update. Scand J Rheumatol 1996;25: 341-4.
3. Goldman ID, Matherly LH. The cellular pharmacology of methotrexate. Pharmacol Ther 1985;28:77-102.
4. Antony AC. The biological chemistry of folate receptors. Blood 1992;79:2807-20.
5. Furst DE. The rational use of methotrexate in rheumatoid arthritis and other rheumatic diseases. Br J Rheumatol 1997;36:1196-204.
6. Cronstein BN, Merrill JT. Mechanisms of the effects of methotrexate. Bull Rheum Dis 1996;45:6-8.
7. Nesher G, Osborn TG, Moore TL. In vitro effects of methotrexate on polyamine levels in lymphocytes from rheumatoid arthritis patients. Clin Exp Rheumatol 1996;14:395-9.
8. Rosowsky A, Wright JE, Cucchi CA, Lippke JA. Tantravahi R, Ervin TJ, et al. Phenotypic heterogenity in cultured human head and neck squamous cell carcinoma lines with low-level methotrexate resistance. Cancer Res 1985;45:6205-12.
9. Hill BT, Bailey BD, White JC, Goldman ID. Characteristics of transport of 4-amino antifolates and folate compounds by two lines of L5178Y lymphoblasts, one with impaired transport of methotrexate. Cancer Res 1979;39:2440-6.
10. Wong SC, Proefke SA, Bhushan A, Matherly LH. Isolation of human cDNAs that restore methotrexate sensitivity and reduced folate carrier activity in methotrexate transport-defective Chinese hamster ovary cells. J Biol Chem 1995;270:17468-75.
11. Matherly LH, Wong SC, Angeles SM, Taub JW, Smith GK. Distribution of the reduced folate carrier (RFC) versus the high affinity membrane folate binding protein (mFBP) in human tumors and tissues. Proc Am Assoc Cancer Res 1994;35:307.
12. Sadasivan E, Rothenberg SP. The complete amino acid sequence of a human folate binding protein from KB cells determined from the cDNA. J Biol Chem 1989;264:5806-11.
13. Elwood PC. Molecular cloning and characterization of the human folate-binding protein cDNA from placenta and malignant tissue culture (KB) cells. J Biol Chem 1989;264:14893-901.
14. Ratnam M, Marquardt H, Duhring JL, Freisheim JH. Homologous membrane folate binding proteins in human placenta: cloning and sequence of a cDNA. Biochemistry 1989;28:8249-54.
15. Shen F, Ross JF, Wang X, Ratnam M. Identification of a novel folate receptor, a truncated receptor, and receptor type beta in hematopoietic cells: cDNA cloning, expression, immunoreactivity, and tissue specificity. Biochemistry 1994;33:1209-15.
16. Ross JF, Chaudhuri PK, Ratnam M. Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines: physiologic and clinical implications. Cancer 1994;73:2432-43.
17. Weitman SD, Lark RH, Coney LR, Fort DW, Frasca V, Zurawski VR Jr, et al. Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. Cancer Res 1992;52:3396-401.
18. Ross JF, Wang H, Behm FG, Mathew P, Wu M, Booth R, et al. Folate receptor type beta is a neutrophilic lineage marker and is differentially expressed in myeloid leukemia. Cancer 1999;85:348-57.
19. Verma RS, Antony AC. Immunoreactive folate-binding proteins from human saliva: isolation and comparison of two distinct species. Biochem J 1992;286:707-15.
20. Shen F, Wu M, Ross JF, Miller D, Ratnam M. Folate receptor type gamma is primarily a secretory protein due to lack of an efficient signal for glycosylphosphatidylinositol modification: protein characterization and cell type specificity. Biochemistry 1995; 34:5660-5.
21. Chung KN, Saikawa Y, Paik TH, Dixon KH, Mulligan T, Cowan KH, et al. Stable transfectants of human MCF-7 breast cancer cells with increased levels of the human folate receptor exhibit an increased sensitivity to antifolates. J Clin Invest 1993;91:1289-94.
22. Spinella MJ, Brigle KE, Sierra EE, Goldman ID. Distinguishing between folate receptor-alpha-mediated transport and reduced folate carrier-mediated transport in L1210 leukemia cells. J Biol Chem 1995;270:7842-9.
23. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS. et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
24. Matsuyama T, Nakashima N, Matsuda T, Nakamura H, Uchida S, Abe T. Induction of multinucleated giant cells from rheumatoid arthritis (RA) synovial adherent cells by anti-DR antibody. Clin Exp Immunol 1994;98:257-63.
25. Yu S, Nakashima N, Xu BH, Matsuda T, Izumihara A, Sunahara N, et al. Pathological significance of elevated soluble CD14 production in rheumatoid arthritis: in the presence of soluble CD14, lipopolysaccharides at low concentrations activate RA synovial fibroblasts. Rheumatol Int 1998;17:237-43.
26. Schwende H, Fitzke E, Ambs P, Dieter P. Differences in the state of differentiation of THP-1 cells induced by phorbol ester and 1.25-dihydroxyvitamin D3. J Leukoc Biol 1996;59:555-61.
27. Miotti S, Canevari S, Menard S, Mezzanzanica D, Porro G, Pupa SM, et al. Characterization of human ovarian carcinoma-associated antigens defined by novel monoclonal antibodies with tumor-restricted specificity. Int J Cancer 1987;39:297-303.
28. Fry DW, Goldman ID. Further studies on the charge-related alterations of methotrexate transport in Ehrlich ascites tumor cells by ionic liposomes: correlation with liposome-cell association. J Membr Biol 1982;66:87-95.
29. Corona G, Giannini F, Fabris M, Toffoli G, Boiocchi M. Role of folate receptor and reduced folate carrier in the transport of 5-methyltetrahydrofolic acid in human ovarian carcinoma cells. Int J Cancer 1998;75:125-33.
30. Kitani A, Nakashima N, Matsuda T, Xu B, Yu S, Nakamura T, et al. T cells bound by vascular cell adhesion molecule-1/CD106 in synovial fluid in rheumatoid arthritis: inhibitory role of soluble vascular cell adhesion molecule-1 in T cell activation. J Immunol 1996;156:2300-8.
31. Prasad PD, Ramamoorthy S, Moe AJ, Smith CH, Leibach FH, Ganapathy V. Selective expression of the high-affinity isoform of the folate receptor (FR-alpha) in the human placental syncytiotrophoblast and choriocarcinoma cells. Biochim Biophys Acta 1994; 1223:71-5.
32. Page ST, Owen WC, Price K, Elwood PC. Expression of the human placental folate receptor transcript is regulated in human tissues: organization and full nucleotide sequence of the gene. J Mol Biol 1993;229:1175-83.
33. Bologna C, Edno L, Anaya J-M, Canovas F, Berghe MV, Jorgensen C, et al. Methotrexate concentrations in synovial membrane and trabecular and cortical bone in rheumatoid arthritis patients. Arthritis Rheum 1994;37:1770-3.
34. Goldman ID. The characteristics of the membrane transport of amethopterin and the naturally occurring folates. Ann N Y Acad Sci 1971;186:400-22.
35. Kane MA, Elwood PC, Portillo RM, Antony AC, Najfeld V, Finley A, et al. Influence of immunoreactive folate-binding proteins of extracellular folate concentration in cultured human cells. J Clin Invest 1988;81:1398-406.
36. Sadasivan E, Cedeno MM, Rothenberg SP. Characterization of the gene encoding a folate-binding protein expressed in human placenta: identification of promoter activity in a G-rich SP1 site linked with the tandemly repeated GGAAG motif for the cts encoded GA-binding protein. J Biol Chem 1994;269:4725-35.
37. Shen F, Wang H, Zheng X, Ratnam M. Expression levels of functional folate receptors alpha and beta are related to the number of N-glycosylated sites. Biochem J 1997;327:759-64.
38. Sierra EE, Brigle KE, Spinella MJ, Goldman ID. pH dependence of methotrexate transport by the reduced folate carrier and the folate receptor in L1210 leukemia cells: further evidence for a third route mediated at low pH. Biochem Pharmacol 1997;53:223-31.
39. Bannwarth B, Labat L, Moride Y, Schaeverbeke T. Methotrexate in rheumatoid arthritis: an update. Drugs 1994;47:25-50.
40. Genestier L, Paillot R, Fournel S, Ferraro C, Miossec P, Revillard JP. Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells. J Clin Invest 1998;102:322-8.
41. Burmester GR, Stuhlmüller B, Keyszer G, Kinne RW. Mononuclear phagocytes and rheumatoid synovitis: mastermind or workhorse in arthritis? Arthritis Rheum 1997;40:5-18.
42. Wang X, Shen F, Freisheim JH, Gentry LE, Ratnam M. Differential stereospecificities and affinities of folate receptor isoforms for folate compounds and antifolates. Biochem Pharmacol 1992; 44:1898-901.
43. Bologna C, Viu P, Picot MC, Jorgensen C, Sany J. Long-term follow-up of 453 rheumatoid arthritis patients treated with methotrexate: an open, retrospective, observational study. Br J Rheumatol 1997;36:535-40.
44. Harding MJ, Cantwell BM, Milstead RA, Harris AL, Kaye SB. Phase II study of the thymidylate synthetase inhibitor CB3717 (N10-propargyl-5,8-dideazafolic acid) in colorectal cancer. Br J Cancer 1988;57:628-9.
45. Laohavinij S, Wedge SR, Lind MJ, Bailey N, Humphreys A, Proctor M, et al. A phase I clinical study of the antipurine antifolate lometrexol (DDATHF) given with oral folic acid. Invest New Drugs 1996;14:325-35.